PMID- 35307723
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20230925
IS  - 1536-0229 (Electronic)
IS  - 0363-9762 (Linking)
VI  - 47
IP  - 5
DP  - 2022 May 1
TI  - Role of 68Ga-DOTATOC PET/CT in Insulinoma According to 3 Different Contexts: A 
      Retrospective Study.
PG  - 394-401
LID - 10.1097/RLU.0000000000004126 [doi]
AB  - OBJECTIVE: The aim of this study was to assess the performance of 68Ga-DOTATOC 
      PET/CT in the detection and extension of insulinomas according to 3 different 
      contexts: sporadic benign, sporadic metastatic, and multiple endocrine neoplasia 
      type 1 (MEN1). PATIENTS AND METHODS: The data of 71 adult patients who underwent 
      68Ga-DOTATOC PET/CT for suspected or confirmed sporadic insulinoma, suspicion of 
      insulinoma in the context of MEN1, follow-up of metastatic insulinoma, or 
      suspicion of recurrence of insulinoma were retrospectively analyzed. Pathological 
      examination or strong clinical and biological findings were used as standards of 
      truth. RESULTS: For the assessment of a confirmed sporadic insulinoma in 17 
      patients, the sensitivity of SR-PET was 75%, including 2 patients for whom 
      metastatic lesions had been revealed by SR-PET. For 35 patients with a suspicion 
      of insulinoma, the sensitivity was 39%. In 10 patients followed up for metastatic 
      insulinoma, the sensitivity was 100%. For 5 patients with a history of MEN1, 
      interpretation of SR-PET was difficult, as 3 of them presented with multiple 
      pancreatic uptake foci. The global sensitivity of SR-PET in all insulinomas 
      excluding those with a MEN1 story was 64% (100% for metastatic insulinomas, 62% 
      for benign insulinomas), with a specificity of 89%. CONCLUSIONS: 68Ga-DOTATOC 
      PET/CT is a useful examination tool for the assessment of insulinomas in selected 
      contexts, with very high performance for the detection and extension workup of 
      metastatic insulinomas and high specificity for the detection of sporadic benign 
      insulinomas. The examination should be completed with GLP-1 receptor PET when it 
      is negative or in a MEN1 context.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Moreau, Pierre-Louis
AU  - Moreau PL
AD  - From the Service de Medecine Nucleaire, Hopital Tenon AP-HP and Sorbonne 
      University.
FAU - Aveline, Cyrielle
AU  - Aveline C
AD  - From the Service de Medecine Nucleaire, Hopital Tenon AP-HP and Sorbonne 
      University.
FAU - Christin-Maitre, Sophie
AU  - Christin-Maitre S
AD  - Endocrinology, Hopital Saint-Antoine AP-HP and Sorbonne University, Paris.
FAU - Chanson, Philippe
AU  - Chanson P
AD  - Endocrinology, Hopital Bicetre AP-HP and University Paris Sud, Le 
      Kremlin-Bicetre.
FAU - Dubreuil, Olivier
AU  - Dubreuil O
AD  - Department of Digestive Oncology, Groupe Hospitalier Diaconesses Croix 
      Saint-Simon, Paris, France.
FAU - Rusu, Timofei
AU  - Rusu T
AD  - From the Service de Medecine Nucleaire, Hopital Tenon AP-HP and Sorbonne 
      University.
FAU - Montravers, Francoise
AU  - Montravers F
AD  - From the Service de Medecine Nucleaire, Hopital Tenon AP-HP and Sorbonne 
      University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Nucl Med
JT  - Clinical nuclear medicine
JID - 7611109
RN  - 0 (Ga(III)-DOTATOC)
RN  - 0 (Organometallic Compounds)
RN  - RWM8CCW8GP (Octreotide)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Insulinoma/diagnostic imaging
MH  - Octreotide/analogs & derivatives
MH  - Organometallic Compounds
MH  - *Pancreatic Neoplasms/diagnostic imaging/pathology
MH  - Positron Emission Tomography Computed Tomography
MH  - Retrospective Studies
COIS- Conflicts of interest and sources of funding: none declared.
EDAT- 2022/03/22 06:00
MHDA- 2022/04/08 06:00
CRDT- 2022/03/21 05:44
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
PHST- 2022/03/21 05:44 [entrez]
AID - 00003072-202205000-00002 [pii]
AID - 10.1097/RLU.0000000000004126 [doi]
PST - ppublish
SO  - Clin Nucl Med. 2022 May 1;47(5):394-401. doi: 10.1097/RLU.0000000000004126.